Phibro Animal Health (NASDAQ:PAHC) Shares Gap Up – What’s Next?

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) gapped up prior to trading on Wednesday . The stock had previously closed at $28.52, but opened at $29.94. Phibro Animal Health shares last traded at $30.00, with a volume of 41,780 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PAHC shares. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a research report on Friday, February 6th. Weiss Ratings cut shares of Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 8th. Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Citigroup decreased their target price on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Finally, Zacks Research downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Phibro Animal Health has a consensus rating of “Hold” and an average target price of $38.80.

Phibro Animal Health Trading Up 5.9%

The company has a 50-day moving average price of $48.00 and a two-hundred day moving average price of $45.53. The stock has a market cap of $1.22 billion, a P/E ratio of 12.96, a P/E/G ratio of 0.45 and a beta of 0.46. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04. The company had revenue of $383.54 million during the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, research analysts expect that Phibro Animal Health Corporation will post 3.07 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd will be issued a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Wednesday, June 3rd. Phibro Animal Health’s dividend payout ratio (DPR) is 20.60%.

Insider Activity at Phibro Animal Health

In related news, CEO Jack Bendheim sold 10,560 shares of the company’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $52.68, for a total transaction of $556,300.80. Following the transaction, the chief executive officer directly owned 80,360 shares in the company, valued at approximately $4,233,364.80. This represents a 11.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 74,928 shares of company stock worth $4,017,273. 50.13% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Penserra Capital Management LLC bought a new stake in shares of Phibro Animal Health during the 3rd quarter worth approximately $519,000. JPMorgan Chase & Co. grew its position in Phibro Animal Health by 1,730.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock valued at $9,634,000 after acquiring an additional 225,110 shares during the last quarter. Citigroup Inc. grew its position in Phibro Animal Health by 112.3% in the 3rd quarter. Citigroup Inc. now owns 54,941 shares of the company’s stock valued at $2,223,000 after acquiring an additional 29,066 shares during the last quarter. Advisors Preferred LLC purchased a new stake in Phibro Animal Health in the third quarter worth $3,953,000. Finally, Public Sector Pension Investment Board lifted its position in shares of Phibro Animal Health by 14.7% during the third quarter. Public Sector Pension Investment Board now owns 79,478 shares of the company’s stock worth $3,216,000 after purchasing an additional 10,184 shares during the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.